Takeda Oncology’s Ninlaro 1Point
program offers comprehensive services that can assist patients with the financial burden and other day-to-day needs associated with Ninlaro
(ixazomib) treatment. Ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 1 previous therapy.
[ Read More ]